Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Flexion Therapeutics (FLXN)

Flexion Therapeutics (FLXN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 458,927
  • Shares Outstanding, K 50,321
  • Annual Sales, $ 85,550 K
  • Annual Income, $ -113,710 K
  • 60-Month Beta 1.53
  • Price/Sales 5.38
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade FLXN with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.91
  • Most Recent Earnings N/A on 11/12/21
  • Next Earnings Date 11/17/21
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 0.00% ( unch)
  • Historical Volatility 8.06%
  • IV Percentile 0%
  • IV Rank N/A
  • IV High 0.00% on N/A
  • IV Low 0.00% on N/A
  • Put/Call Vol Ratio N/A
  • Today's Volume N/A
  • Volume Avg (30-Day) N/A
  • Put/Call OI Ratio N/A
  • Today's Open Interest N/A
  • Open Int (30-Day) N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.53
  • Number of Estimates 4
  • High Estimate -0.43
  • Low Estimate -0.61
  • Prior Year -0.40
  • Growth Rate Est. (year over year) -32.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.10 +0.22%
on 11/10/21
9.43 -3.29%
on 10/22/21
-0.19 (-2.04%)
since 10/18/21
3-Month
4.30 +112.09%
on 08/20/21
9.89 -7.79%
on 10/11/21
+4.37 (+92.00%)
since 08/18/21
52-Week
4.30 +112.09%
on 08/20/21
13.66 -33.24%
on 01/15/21
-1.88 (-17.09%)
since 11/18/20

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ECHO, ACBI, HRC, FLXN; Shareholders are Encouraged to Contact the Firm

NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Echo Global Logistics, Inc. (NASDAQ:ECHO) concerning...

ECHO : 48.24 (+0.04%)
ACBI : 30.98 (-1.56%)
HRC : 155.96 (+0.03%)
FLXN : 9.12 (-0.22%)
Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark

Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.

ENDP : 3.30 (-1.20%)
PCRX : 65.20 (+2.07%)
ENTA : 59.44 (+3.28%)
FLXN : 9.12 (-0.22%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FTSI, UMPQ, FLXN, ADMS; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: FTS International, Inc. (NYSE:...

UMPQ : 20.73 (-1.24%)
FLXN : 9.12 (-0.22%)
ADMS : 8.22 (+0.74%)
FTSI : 26.33 (+0.04%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

ADMS : 8.22 (+0.74%)
FLXN : 9.12 (-0.22%)
AZPN : 152.23 (+0.55%)
EBMT : 23.61 (+0.47%)
Flexion (FLXN) to Report Q3 Earnings: What's in the Cards?

On Flexion's (FLXN) third-quarter earnings call, investor focus will be on its updates on earnings and revenues and the upcoming merger with Pacira whereby the latter will acquire the former.

PCRX : 65.20 (+2.07%)
FLXN : 9.12 (-0.22%)
ARDX : 0.8760 (-1.57%)
GMTX : 2.0222 (+2.13%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates FLXN, AZPN, COLB, LMRK; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Flexion Therapeutics, Inc. (NASDAQ:...

FLXN : 9.12 (-0.22%)
AZPN : 152.23 (+0.55%)
COLB : 35.62 (-1.85%)
LMRK : 16.49 (+0.30%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds ADMS, FLXN, AZPN, and EBMT Shareholders About Its Ongoing Investigations

/PRNewswire/ -- If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this...

ADMS : 8.22 (+0.74%)
FLXN : 9.12 (-0.22%)
AZPN : 152.23 (+0.55%)
EBMT : 23.61 (+0.47%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates ADMS, FLXN, ACBI, SQ; Shareholders are Encouraged to Contact the Firm

/PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Adamas Pharmaceuticals, Inc....

ADMS : 8.22 (+0.74%)
FLXN : 9.12 (-0.22%)
ACBI : 30.98 (-1.56%)
SQ : 129.13 (-0.67%)
FLEXION THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Flexion Therapeutics, Inc. - FLXN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Flexion Therapeutics, Inc. (NasdaqGM: FLXN)...

FLXN : 9.12 (-0.22%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates Flexion Therapeutics, Inc.

/PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Flexion...

FLXN : 9.12 (-0.22%)
PCRX : 65.20 (+2.07%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Flexion Therapeutics, Inc. is a specialty pharmaceutical company. It is focused on the development and commercialization of injectable pain therapies. The Company is targeting anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It operates in the United...

See More

Key Turning Points

3rd Resistance Point 9.30
2nd Resistance Point 9.26
1st Resistance Point 9.19
Last Price 9.12
1st Support Level 9.09
2nd Support Level 9.05
3rd Support Level 8.98

See More

52-Week High 13.66
Fibonacci 61.8% 10.08
Last Price 9.12
Fibonacci 50% 8.98
Fibonacci 38.2% 7.88
52-Week Low 4.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar